Market Overview

Stem Cell Therapeutics Special Meeting of Shareholders


TORONTO, ONTARIO--(Marketwire - Dec. 4, 2012) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") a life sciences development company of stem cell-related therapeutics, today announced a reminder that a Special Meeting of Shareholders will be held in the Offices of McCarthy Tetrault LLP, Toronto Dominion Bank Tower, 66 Wellington Street West, 53rd Floor, J.J. Robinette Boardroom, Toronto, ON M5K 1E6, on Thursday, December 20, 2012, at 10:00 a.m. Eastern Time.

The Special Meeting will consider resolutions set forth in the Management Information Circular dated November 22, 2012, accessible on SEDAR at Interested shareholders, unable to attend the meeting in person, can listen to the proceedings live via conference call.

Stem Cell Therapeutics has provided a corporate update for its shareholders, which is available on the Investors page of the Company's website: Mr. David Allan, Executive Chairman of Stem Cell Therapeutics will also host a question and answer session following the Special Meeting. Conference call participants wishing to ask a question will be instructed by the operator on how to do so at this time.

Details to listen live:

Date: Thursday, December 20, 2012
Time: 10:00 a.m. ET
Dial-in Number: (647) 427-7450 or (888) 231-8191
Taped Replay: (416) 849-0833 or (855) 859-2056
Reference Number: 77609672

About Stem Cell Therapeutics

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) is a Canadian commercialization receptor company in the business of developing stem cell-based therapeutics through partnerships with research institutions or technology transfer organizations. The Company's corporate objectives include the analysis and acquisition of additional stem cell-related development opportunities and securing capital for the advancement of the licensed or acquired products. In October 2012 SCT became a member of the 20-member Centre for Commercialization of Regenerative Medicine ("CCRM") consortium. SCT has extensive expertise and experience in the stem cell biotechnology sector based on the intellectual property of Dr. Samuel Weiss in stem cell research. SCT proposes to build upon the foundational technologies by acquiring additional early-stage clinical or late-stage preclinical candidates. SCT's Traumatic Brain Injury product, NTx(R)-428, is currently in a Phase II clinical trial. For more information, visit:

Caution Regarding Forward-Looking Information:

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the "forward-looking statements"). These forward-looking statements relate to, among other things, SCT's objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to, the availability of capital, changes in capital markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, unproven markets for technologies in development, the cost and supply of raw materials, management of growth, effects of payers'' willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading "Risk Factors" contained in SCT's 2010 annual information form. SCT cautions that the foregoing list of important factors that may affect future results is not exhaustive.

When relying on SCT's forward-looking statements to make decisions with respect to SCT, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of financing for research and development companies in addition to general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, SCT cannot provide assurance that actual results will be consistent with these forward-looking statements. SCT undertakes no obligation to update or revise any forward-looking statement.

Stem Cell Therapeutics Corp.
David Allan
Executive Chairman

View Comments and Join the Discussion!

Partner Center